BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 19474714)

  • 1. Catabolism of lipoproteins and metabolic syndrome.
    Therond P
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
    Adiels M; Olofsson SO; Taskinen MR; Borén J
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis and management of the dyslipidemia of the metabolic syndrome.
    Raal FJ
    Metab Syndr Relat Disord; 2009 Apr; 7(2):83-8. PubMed ID: 19400742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dyslipidemia and atherosclerosis].
    Koba S; Hirano T
    Nihon Rinsho; 2011 Jan; 69(1):138-43. PubMed ID: 21226274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.
    Chan DC; Barrett PH; Watts GF
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The surprising AIM-HIGH results are not surprising when viewed through a particle lens.
    Otvos JD
    J Clin Lipidol; 2011; 5(5):368-70. PubMed ID: 21981836
    [No Abstract]   [Full Text] [Related]  

  • 9. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipid management--treatment goal and strategy].
    Koshiyama H
    Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C; Olsson AG
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome.
    Volek JS; Fernandez ML; Feinman RD; Phinney SD
    Prog Lipid Res; 2008 Sep; 47(5):307-18. PubMed ID: 18396172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology of Diabetic Dyslipidemia.
    Hirano T
    J Atheroscler Thromb; 2018 Sep; 25(9):771-782. PubMed ID: 29998913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets.
    Ng DS
    Can J Diabetes; 2013 Oct; 37(5):319-26. PubMed ID: 24500559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M
    Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lipid triad, or how to reduce residual cardiovascular risk?
    Girard-Mauduit S
    Ann Endocrinol (Paris); 2010 Mar; 71(2):89-94. PubMed ID: 20303470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of niacin.
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.